Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mag2 is a range of magnesium-based products developed by Cooperation Pharmaceutique Francaise (Cooper Consumer Health). The brand encompasses both over-the-counter (OTC) medications and dietary supplements designed to address magnesium deficiency and its associated symptoms, such as nervousness, irritability, mild anxiety, temporary fatigue, and minor sleep disturbances. The core pharmaceutical formulation, often provided as an oral solution in ampoules, typically contains magnesium pidolate. Other variants, such as Mag2 24h, utilize a combination of magnesium carbonate and magnesium oxide to provide a sustained release of elemental magnesium over a 24-hour period. Many products in the Mag2 line also include Vitamin B6 (pyridoxine) to enhance the intestinal absorption of magnesium and support normal psychological and nervous system function. Mag2 is a leading brand in the French consumer health market and is available in various dosage forms including tablets, sachets, and gummies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mag2.